- Generic name
- Levetiracetam
- Strength
- 250 mg
- Dosage form
- Tablet
- Manufactured by
- Opsonin Pharma Limited
Levefix 250 Tablet
About Levefix 250 Tablet
Levefix 250 is a tablet from Opsonin Pharma Limited, with the generic name Levetiracetam. It is prescribed for partial-onset seizures, which may or may not spread to other parts of the brain.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Levefix 250 Tablet?
Levefix 250 250 mg tablet is a medicine made by Opsonin Pharma Limited. It contains levetLevefix 250am, which belongs to a group of medicines called adjunct anti-epileptic drugs. It is thought to attach to specific proteins in the brain and help regulate the way nerve signals fire, which can reduce the chance of seizures spreading. The doctor decides the right dose and course for each person.
Uses of Levefix 250
It is prescribed for partial-onset seizures, which may or may not spread to other parts of the brain. Levefix 250 250 mg tablet is used to treat epilepsy. The doctor decides whether it is suitable and how it should be included in the overall treatment plan.
How to use Levefix 250
Try to take it at the same times each day so it becomes part of your routine. Swallow the tablet with water. Levefix 250 is taken by mouth. Do not crush or chew the tablet. Do not change the amount you take or stop the medicine on your own, since stopping epilepsy treatment suddenly can be harmful. Do not change the amount you take or stop the medicine on your own, because stopping suddenly can make seizures worse.
Side effects of Levefix 250
Do not adjust the amount you take to manage side effects without speaking to the doctor first. In adults, common side effects include sleepiness, weakness, infection and dizziness. If you notice any side effect that bothers you or does not go away, tell your doctor or pharmacist. Do not stop the medicine without medical advice.
Safety and precautions
Rarely, this medicine has been linked with kidney injury and with reduced blood cell counts, so report unusual tiredness, fever or bruising. It is not recommended during pregnancy, or in women who could become pregnant and are not using contraception, unless the doctor decides it is clearly necessary. It passes into breast milk, so breastfeeding is not recommended unless the doctor decides the benefits outweigh the risks. Ask your doctor first if any of these apply to you.
Frequently asked questions
Why is Levefix 250 prescribed?
It is prescribed for partial-onset seizures, which may or may not spread to other parts of the brain. Levefix 250 250 mg tablet is used to treat epilepsy.
How should I take Levefix 250?
Try to take it at the same times each day so it becomes part of your routine. Swallow the tablet with water.
Can Levefix 250 cause side effects?
Do not adjust the amount you take to manage side effects without speaking to the doctor first. In adults, common side effects include sleepiness, weakness, infection and dizziness.
Can I use Levefix 250 in pregnancy or while breastfeeding?
Rarely, this medicine has been linked with kidney injury and with reduced blood cell counts, so report unusual tiredness, fever or bruising. It is not recommended during pregnancy, or in women who could become pregnant and are not using contraception, unless the doctor decides it is clearly necessary.
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.